Portal Biotechnologies Secures Major Seed Funding
Recently, Portal Biotechnologies, Inc., a groundbreaking company specializing in cell engineering, revealed a successful seed funding round totaling $7 million. This oversubscribed funding was prominently led by IA Ventures, with contributions from notable investors including Pear VC, Undeterred Ventures, and Page One VC. This financial boost signals a significant milestone for Portal as it continues to expand its innovative approaches in cellular delivery methods.
A New Era in Cell Engineering
Portal is at the forefront of simplifying intracellular delivery, a critical aspect of modern biotechnology. The company’s focus lies in enhancing cell engineering and analytical capabilities, which is vital for both research and clinical applications. Their product suite, built on advanced mechanical delivery technology, is designed to deliver an array of molecules into various cell types. This innovative technique allows for the simultaneous delivery of small molecules, polypeptides, RNA, gene editing components, and antibodies, unlocking new possibilities for multiplexed cell function modification.
Partnerships and Collaborations
Since its inception from the stealth phase, Portal has formed collaborations with over 50 biopharma and academic partners. These partnerships are instrumental in applying Portal’s technological advancements to an array of fields, from developing novel drug screening methods to engineering sophisticated cell therapies. Impressively, seven of the top ten pharmaceutical companies are leveraging Portal’s platform, underscoring the company’s impact within the industry.
Expanding Influence and Integration
Additionally, Portal is a member of the Bayer Co.Lab, situated in Cambridge, and maintains affiliations with the Roche Accelerator in Shanghai. Through its ‘Powered by Portal’ initiative, the company is strategically integrating single-use cartridges with high-throughput robotic systems and clinical equipment providers. This approach not only amplifies the effectiveness of their technology but also enhances accessibility for researchers and clinicians alike.
A Vision for the Future
Armon Sharei, Ph.D., the founder and CEO of Portal, shared his excitement about the rapid expansion and adoption of their platform. He expressed profound gratitude to their investors and early adopters for their trust as Portal strives to democratize access to groundbreaking technology. Sharei’s journey is particularly personal as a former cancer patient, and his motivation drives his commitment to enabling innovative therapeutic solutions through Portal’s advanced capabilities.
Strengthening the Leadership Team
To propel the company’s commercial efforts forward, Dr. Anil Narasimha has recently joined as the Chief Commercial Officer. Having previously co-founded and served as CEO of Mekonos, Dr. Narasimha brings invaluable insight into the ex-vivo drug delivery landscape. Together with Portal's seasoned leadership including Sharei and COO Alec Barclay, the company is poised for substantial growth and enhanced collaborative opportunities across diverse disease areas.
About Portal Biotechnologies
Portal Biotechnologies is dedicated to revolutionizing the field of cell engineering through innovative intracellular delivery solutions. Their proprietary mechanical delivery system is capable of transporting numerous types of cargo across various cell types effectively. By utilizing transient membrane perturbation through specially designed silicon surfaces, they pave the way for significant advancements in biological research and cellular therapeutics. For those looking to explore their cutting-edge technologies further, more information is available on their website.
Frequently Asked Questions
What is Portal Biotechnologies?
Portal Biotechnologies is a cell engineering platform company focused on enhancing cellular delivery methods for research and clinical applications.
Who led the recent funding round for Portal?
IA Ventures led the oversubscribed $7 million seed funding round for Portal Biotechnologies.
What type of partners does Portal work with?
Portal has partnered with over 50 biopharma and academic organizations, including seven of the top ten pharmaceutical companies.
What is the significance of their ‘Powered by Portal’ initiative?
This initiative aims to integrate Portal’s technology with high-throughput robotics and clinical equipment providers to enhance accessibility and efficiency.
Who is the CEO of Portal Biotechnologies?
The CEO of Portal Biotechnologies is Armon Sharei, Ph.D., who is also one of the founders of the company.
